New surgical technique is effective for keratoconus

Article

For the management of keratoconus, diamond-knife?assisted DALK is effective and predictable in patients with keratoconus, and may offer visual and refractive outcomes that are similar to those achieved with big-bubble DALK, according to a recently published study.

For the management of keratoconus, diamond-knife–assisted DALK is effective and predictable in patients with keratoconus, and may offer visual and refractive outcomes that are similar to those achieved with big-bubble DALK, according to a study recently published in the Journal of Cataract & Refractive Surgery.

Diamond-knife–assisted DALK is the most recent variation of DALK for cornea replacement, and is preceded by the big-bubble technique, in which air is injected into the corneal stroma to isolate Desçemet's membrane.

Researchers performed diamond-knife–assisted DALK in 19 eyes and big-bubble DALK in 11 eyes successfully. At 6 months, mean corrected distance visual acuity (CDVA) improved significantly, from 1.87 logMAR to 0.23 logMAR (P = 0.05). In addition, mean keratometry improved from 65.99 D to 45.13 D, and the mean keratometric cylinder improved from 7.99 D to 2.87 D (P = 0.05 for both).

Postoperatively, mean refractive astigmatism was 2.55 D and the mean spherical equivalent was -1.97 D. When comparisons were made between diamond-knife–assisted DALK and big-bubble DALK, the following values were comparable: CDVA (P = 0.06), postoperative keratometry (P = 0.64), refractive cylinder (P = 0.63), and endothelial cell loss (P = 0.11).

All surgeries were completed successfully, and there were no intraoperative or postoperative complications with the diamond-knife–assisted DALK.

To access the abstract of this study, click here.

Recent Videos
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
© 2024 MJH Life Sciences

All rights reserved.